RSS Feed ALL

Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

about 3 hours ago

Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis

1 day ago

Submission is supported by 24-week results from the Phase 3b APEX study...

Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions

1 day ago

Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional...

Johnson & Johnson to Participate in the 2025 Wells Fargo Healthcare Conference

6 days ago

Johnson & Johnson showcases latest advancements in Alzheimer’s research at AAIC 2025

6 days ago

Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company’s leadership...

European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma

7 days ago

Landmark approval is based on results from the Phase 3 AQUILA study...

European Commission approves IMBRUVICA® (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant

7 days ago

Ibrutinib is the first approved Bruton’s tyrosine kinase (BTK) inhibitor to demonstrate...

Johnson & Johnson Announces Strategic Agreement with Pacira BioSciences to Expand Early Intervention Offering for Osteoarthritis of the Knee

8 days ago

Agreement enhances the Early Intervention portfolio to tackle the increasing burden of...

Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis

9 days ago

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the...

Johnson & Johnson Unveils Global Insights on the Future of Surgical Software

13 days ago

Survey of nearly 700 clinicians across more than 600 surgical facilities in...

Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer

13 days ago

New Drug Application supported by results from the Phase 2b SunRISe-1 study

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

15 days ago